Roivant Sciences’ subsidiary, Pulmovant, has secured global rights to mosliciguat, an inhaled sGC activator for pulmonary hypertension (PH). Initial Phase 1b trial results show significant reductions in pulmonary vascular resistance, highlighting the potential of this therapy for PH-ILD patients.